Table 1.
Patient and Transplant Characteristics at Allo-SCT
| Characteristic | Percent |
|---|---|
| Gender | |
| Female | 56 |
| Male | 44 |
| Ethnicity | |
| Non-Hispanic | 49 |
| Hispanic | 48 |
| Not stated | 2 |
| Transplant indications | |
| CML | 46 |
| AML | 23 |
| MDS | 14 |
| ALL | 9 |
| NHL/CLL | 4 |
| SAA | 1.4 |
| CMML | 1.4 |
| Mastocytosis | .7 |
| Graft source | |
| PBSC (ex vivo T cell depleted) | 81.9 |
| Bone marrow | 11.6 |
| PBSC (unmanipulated) | 6.5 |
| Intensity of conditioning | |
| Myeloablative | 94.9 |
| Nonmyeloablative | 5.1 |
| TBI (cGy) | |
| 0 | 6.5 |
| 400 | 2.2 |
| 1200–1360 | 91 |
| TBI dose to lungs | |
| 0 | 6.5 |
| 400–600 | 35.5 |
| 900 | 15.2 |
| 1360 | 42.8 |
| Busulfan exposure | |
| Yes (all pretransplant) | 4.0 |
| No | 96.0 |
| Smoking history | |
| Pretransplant | 19.5 |
| Post-transplant | 12.2 |
ALL indicates acute lymphoid leukemia; AML, acute myelogenous leukemia; CLL, chronic lymphoid leukemia; CMML, chronic myelomnocytic leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; SAA, severe aplastic anemia.